MR-guided focused ultrasound therapy of extra-abdominal desmoid tumors: a multicenter retrospective study of 105 patients
- PMID: 37615768
- DOI: 10.1007/s00330-023-10073-9
MR-guided focused ultrasound therapy of extra-abdominal desmoid tumors: a multicenter retrospective study of 105 patients
Abstract
Objective: To assess the safety and efficacy of magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment extra-abdominal desmoids.
Methods: A total of 105 patients with desmoid fibromatosis (79 females, 26 males; 35 ± 14 years) were treated with MRgFUS between 2011 and 2021 in three centers. Total and viable tumors were evaluated per patient at last follow-up after treatment. Response and progression-free survival (PFS) were assessed with (modified) response evaluation criteria in solid tumors (RECIST v.1.1 and mRECIST). Change in Numerical Rating Scale (NRS) pain and 36-item Short Form Health Survey (SF-36) scores were compared. Treatment-related adverse events were recorded.
Results: The median initial tumor volume was 114 mL (IQR 314 mL). After MRgFUS, median total and viable tumor volume decreased to 51 mL (95% CI: 30-71 mL, n = 101, p < 0.0001) and 29 mL (95% CI: 17-57 mL, n = 88, p < 0.0001), respectively, at last follow-up (median: 15 months, 95% CI: 11-20 months). Based on total tumor measurements (RECIST), 86% (95% CI: 75-93%) had at least stable disease or better at last follow-up, but 50% (95% CI: 38-62%) of remaining viable nodules (mRECIST) progressed within the tumor. Median PFS was reached at 17 and 13 months for total and viable tumors, respectively. NRS decreased from 6 (IQR 3) to 3 (IQR 4) (p < 0.001). SF-36 scores improved (physical health (41 (IQR 15) to 46 (IQR 12); p = 0.05, and mental health (49 (IQR 17) to 53 (IQR 9); p = 0.02)). Complications occurred in 36%, most commonly 1st/2nd degree skin burns.
Conclusion: MRgFUS reduced tumor volume, reduced pain, and improved quality of life in this series of 105 patients with extra-abdominal desmoid fibromatosis.
Clinical relevance statement: Imaging-guided ablation is being increasingly used as an alternative to surgery, radiation, and medical therapy for the treatment of desmoid fibromatosis. MR-guided high-intensity focused ultrasound is an incisionless ablation technique that can be used to reduce tumor burden effectively and safely.
Key points: • Desmoid fibromatosis was treated with MR-guided high-intensity focused ultrasound in 105 patients. • MR-guided focused ultrasound ablation reduced tumor volume and pain and improved quality of life. • MR-guided focused ultrasound is a treatment option for patients with extra-abdominal desmoid tumors.
Keywords: Ablation techniques; Fibromatosis, aggressive; Musculoskeletal diseases; Neoplasms, connective and soft tissue.
© 2023. The Author(s), under exclusive licence to European Society of Radiology.
References
-
- Reitamo JJ, Hayry P, Nykyri E, Saxen E (1982) The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol. https://doi.org/10.1093/ajcp/77.6.665
-
- Bonvalot S, Desai A, Coppola S, et al (2012) The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol. https://doi.org/10.1093/annonc/mds298
-
- Anneberg M, Svane HML, Fryzek J, et al (2022) The epidemiology of desmoid tumors in Denmark. Cancer Epidemiol. https://doi.org/10.1016/j.canep.2022.102114
-
- Colombo C, Fiore M, Grignani G, et al (2022) A prospective observational study of Active surveillance in primary desmoid fibromatosis. Clin Cancer Res 28(18):4027–4032. https://doi.org/10.1158/1078-0432.CCR-21-4205
-
- Schut AW, Timbergen MJM, van Broekhoven DLM, et al (2022) A nationwide prospective clinical trial on active surveillance in patients with non-intra-abdominal desmoid-type fibromatosis: the GRAFITI Trial. Ann Surg. https://doi.org/10.1097/SLA.0000000000005415
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
